STAAR Surgical (NASDAQ:STAA) Given Average Recommendation of “Hold” by Analysts

Shares of STAAR Surgical (NASDAQ:STAA) have received an average recommendation of “Hold” from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $24.63.

Several research analysts have weighed in on the company. Wells Fargo & Company assumed coverage on STAAR Surgical in a research note on Monday, April 21st. They issued an “equal weight” rating and a $17.00 price target for the company. Jefferies Financial Group downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a report on Thursday, February 27th. Canaccord Genuity Group lifted their target price on STAAR Surgical from $17.00 to $20.00 and gave the stock a “hold” rating in a report on Thursday. Finally, Stephens reissued an “equal weight” rating and set a $17.00 price target on shares of STAAR Surgical in a research note on Tuesday, March 18th.

Insider Activity

In other news, major shareholder Broadwood Partners, L.P. purchased 108,720 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The stock was purchased at an average cost of $17.96 per share, with a total value of $1,952,611.20. Following the purchase, the insider now owns 12,182,995 shares in the company, valued at approximately $218,806,590.20. This trade represents a 0.90 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have purchased 1,742,581 shares of company stock valued at $28,407,543. 1.00% of the stock is currently owned by insiders.

Institutional Trading of STAAR Surgical

Institutional investors have recently added to or reduced their stakes in the company. US Bancorp DE grew its stake in shares of STAAR Surgical by 1,693.0% during the first quarter. US Bancorp DE now owns 2,044 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 1,930 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in STAAR Surgical during the 4th quarter valued at $180,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in STAAR Surgical by 29.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,076 shares of the medical instruments supplier’s stock valued at $248,000 after acquiring an additional 3,217 shares during the last quarter. GAMMA Investing LLC increased its stake in STAAR Surgical by 4,086.0% in the first quarter. GAMMA Investing LLC now owns 14,651 shares of the medical instruments supplier’s stock worth $258,000 after purchasing an additional 14,301 shares during the period. Finally, Bridgefront Capital LLC lifted its position in shares of STAAR Surgical by 27.2% during the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock worth $262,000 after purchasing an additional 2,306 shares during the last quarter. Institutional investors own 96.70% of the company’s stock.

STAAR Surgical Stock Down 0.9 %

NASDAQ STAA opened at $19.36 on Friday. STAAR Surgical has a twelve month low of $13.50 and a twelve month high of $49.86. The business has a 50-day moving average price of $17.57 and a 200-day moving average price of $21.92. The firm has a market cap of $958.82 million, a price-to-earnings ratio of -47.22 and a beta of 0.65.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.